{"pmid":32474047,"title":"Drinking no-links to the severity of COVID-19: a systematic review and meta-analysis.","text":["Drinking no-links to the severity of COVID-19: a systematic review and meta-analysis.","J Infect","Liu, Ming","Gao, Ya","Shi, Shuzhen","Chen, Yamin","Yang, Kelu","Tian, Jinhui","32474047"],"journal":"J Infect","authors":["Liu, Ming","Gao, Ya","Shi, Shuzhen","Chen, Yamin","Yang, Kelu","Tian, Jinhui"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474047","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.jinf.2020.05.042","keywords":["covid-19","drinking","meta-analysis","severity"],"topics":["Diagnosis"],"weight":1,"_version_":1668341932679495681,"score":9.490897,"similar":[{"pmid":32502509,"title":"The association between severe or death COVID-19 and autoimmune disease: a systematic review and meta-analysis.","text":["The association between severe or death COVID-19 and autoimmune disease: a systematic review and meta-analysis.","J Infect","Liu, Ming","Gao, Ya","Zhang, Yuejun","Shi, Shuzhen","Chen, Yamin","Tian, Jinhui","32502509"],"journal":"J Infect","authors":["Liu, Ming","Gao, Ya","Zhang, Yuejun","Shi, Shuzhen","Chen, Yamin","Tian, Jinhui"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32502509","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.jinf.2020.05.065","keywords":["covid-19","meta-analysis","mortality","severity","autoimmune disease"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1668804508820439040,"score":109.59557},{"pmid":32425643,"pmcid":"PMC7233226","title":"Association of inflammatory markers with the severity of COVID-19: a meta-analysis.","text":["Association of inflammatory markers with the severity of COVID-19: a meta-analysis.","Objectives: Studies reported associations of inflammatory markers with the severity of COVID-19, but conclusions were inconsistent. We aimed to provide an overview of the association of inflammatory markers with severity of COVID-19. Methods: We searched PubMed, Embase, Cochrane Library, Wanfang and China National Knowledge Infrastructure (CNKI) database until March 20, 2020. Weighted mean difference (WMD) and 95% confidence intervals (CIs) were pooled using random or fixed-effects models. Results: A total of 16 studies comprising of 3962 patients with COVID-19 were included in our analysis. Random-effect results demonstrated that patients with COVID-19 in nonsevere group had lower levels for CRP (WMD = -41.78 mg/l, 95% CI = [-52.43, -31.13], P < 0.001), PCT (WMD = -0.13 ng/ml, 95% CI = [-0.20, -0.05], P < 0.001), IL-6 (WMD = -21.32 ng/l, 95% CI = [-28.34, -14.31], P < 0.001), ESR (WMD = -8 mm/h, 95% CI = [-14, -2], P = 0.005), SAA (WMD = -43.35 mug/ml, 95% CI = [-80.85, -5.85], P = 0.020) and serum ferritin (WMD = -398.80 mg/l, 95% CI = [-625.89, -171.71], P < 0.001), compared with those in severe group. Moreover, survivors had a lower level for IL-6 than non-survivors (WMD = -4.80 ng/ml, 95% CI = [-5.87, -3.73], P < 0.001). These results were consistent through sensitivity analysis and publication bias assessment. Conclusions: The meta-analysis highlights the association of inflammatory markers with the severity of COVID-19. Measurement of inflammatory markers might assist clinicians to monitor and evaluate the severity and prognosis of COVID-19.","Int J Infect Dis","Zeng, Furong","Huang, Yuzhao","Guo, Ying","Yin, Mingzhu","Chen, Xiang","Xiao, Liang","Deng, Guangtong","32425643"],"abstract":["Objectives: Studies reported associations of inflammatory markers with the severity of COVID-19, but conclusions were inconsistent. We aimed to provide an overview of the association of inflammatory markers with severity of COVID-19. Methods: We searched PubMed, Embase, Cochrane Library, Wanfang and China National Knowledge Infrastructure (CNKI) database until March 20, 2020. Weighted mean difference (WMD) and 95% confidence intervals (CIs) were pooled using random or fixed-effects models. Results: A total of 16 studies comprising of 3962 patients with COVID-19 were included in our analysis. Random-effect results demonstrated that patients with COVID-19 in nonsevere group had lower levels for CRP (WMD = -41.78 mg/l, 95% CI = [-52.43, -31.13], P < 0.001), PCT (WMD = -0.13 ng/ml, 95% CI = [-0.20, -0.05], P < 0.001), IL-6 (WMD = -21.32 ng/l, 95% CI = [-28.34, -14.31], P < 0.001), ESR (WMD = -8 mm/h, 95% CI = [-14, -2], P = 0.005), SAA (WMD = -43.35 mug/ml, 95% CI = [-80.85, -5.85], P = 0.020) and serum ferritin (WMD = -398.80 mg/l, 95% CI = [-625.89, -171.71], P < 0.001), compared with those in severe group. Moreover, survivors had a lower level for IL-6 than non-survivors (WMD = -4.80 ng/ml, 95% CI = [-5.87, -3.73], P < 0.001). These results were consistent through sensitivity analysis and publication bias assessment. Conclusions: The meta-analysis highlights the association of inflammatory markers with the severity of COVID-19. Measurement of inflammatory markers might assist clinicians to monitor and evaluate the severity and prognosis of COVID-19."],"journal":"Int J Infect Dis","authors":["Zeng, Furong","Huang, Yuzhao","Guo, Ying","Yin, Mingzhu","Chen, Xiang","Xiao, Liang","Deng, Guangtong"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425643","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ijid.2020.05.055","keywords":["covid-19","sars-cov-2","inflammatory markers","meta-analysis","severity"],"locations":["Wanfang","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1667252838029328384,"score":95.45142},{"pmid":32410807,"pmcid":"PMC7221373","title":"Impact of Cerebrovascular and Cardiovascular Diseases on Mortality and Severity of COVID-19 - Systematic Review, Meta-analysis, and Meta-regression.","text":["Impact of Cerebrovascular and Cardiovascular Diseases on Mortality and Severity of COVID-19 - Systematic Review, Meta-analysis, and Meta-regression.","Background We conducted this systematic review and meta-analysis to evaluate the latest evidence on the association between cerebrovascular, cardiovascular disease, and poor outcome in patients with Coronavirus Disease 2019 (COVID-19) pneumonia. Methods A comprehensive systematic literature search was performed using PubMed, SCOPUS, EuropePMC, and Cochrane Central Database. The outcome of interest was composite poor outcome that comprised of mortality and severe COVID-19. Results A total of 4448 patients were obtained from 16 studies. Cerebrovascular disease was associated with increased poor composite outcome (RR 2.04 [1.43, 2.91], p<0.001; I(2): 77%). Subgroup analysis revealed that cerebrovascular disease was associated with mortality (RR 2.38 [1.92, 2.96], p<0.001; I(2): 0%) and was borderline significant for severe COVID-19 (RR 1.88 [1.00, 3.51], p=0.05; I(2): 87%). Cardiovascular disease was associated with increased composite poor outcome (RR 2.23 [1.71, 2.91], p<0.001; I(2): 60%), and its mortality (RR 2.25 [1.53, 3.29], p<0.001; I(2): 33%) and severe COVID-19 (RR 2.25 [1.51, 3.36], p<0.001; I(2): 76%) subgroup. Meta-regression demonstrate that the association was not influenced by gender, age, hypertension, diabetes, and respiratory comorbidities. The association between cerebrovascular disease and poor outcome was not affected by cardiovascular diseases and vice versa. Conclusion Cerebrovascular and cardiovascular diseases were associated with increased risk for poor outcome in COVID-19.","J Stroke Cerebrovasc Dis","Pranata, Raymond","Huang, Ian","Lim, Michael Anthonius","Wahjoepramono, Prof Eka Julianta","July, Julius","32410807"],"abstract":["Background We conducted this systematic review and meta-analysis to evaluate the latest evidence on the association between cerebrovascular, cardiovascular disease, and poor outcome in patients with Coronavirus Disease 2019 (COVID-19) pneumonia. Methods A comprehensive systematic literature search was performed using PubMed, SCOPUS, EuropePMC, and Cochrane Central Database. The outcome of interest was composite poor outcome that comprised of mortality and severe COVID-19. Results A total of 4448 patients were obtained from 16 studies. Cerebrovascular disease was associated with increased poor composite outcome (RR 2.04 [1.43, 2.91], p<0.001; I(2): 77%). Subgroup analysis revealed that cerebrovascular disease was associated with mortality (RR 2.38 [1.92, 2.96], p<0.001; I(2): 0%) and was borderline significant for severe COVID-19 (RR 1.88 [1.00, 3.51], p=0.05; I(2): 87%). Cardiovascular disease was associated with increased composite poor outcome (RR 2.23 [1.71, 2.91], p<0.001; I(2): 60%), and its mortality (RR 2.25 [1.53, 3.29], p<0.001; I(2): 33%) and severe COVID-19 (RR 2.25 [1.51, 3.36], p<0.001; I(2): 76%) subgroup. Meta-regression demonstrate that the association was not influenced by gender, age, hypertension, diabetes, and respiratory comorbidities. The association between cerebrovascular disease and poor outcome was not affected by cardiovascular diseases and vice versa. Conclusion Cerebrovascular and cardiovascular diseases were associated with increased risk for poor outcome in COVID-19."],"journal":"J Stroke Cerebrovasc Dis","authors":["Pranata, Raymond","Huang, Ian","Lim, Michael Anthonius","Wahjoepramono, Prof Eka Julianta","July, Julius"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32410807","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jstrokecerebrovasdis.2020.104949","keywords":["covid-19","cardiovascular","cerebrovascular","mortality","severity"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666897319206846464,"score":84.51202},{"pmid":32369203,"title":"Smoking links to the severity of Covid-19: An update of a meta-analysis.","text":["Smoking links to the severity of Covid-19: An update of a meta-analysis.","The paper entitled \"The impact of COPD and smoking history on the severity of Covid-19: A systemic review and meta-analysis.\" published in Journal of Medical Virology on 15 April, 20201. The results revealed the pooled OR of COPD and the development of severe Covid-19 was 4.38 (Fixed effect model, 95% CI: 2.34-8.20), while the OR of ongoing smoking was 1.98 (Fixed effect model, 95% CI: 1.29-3.05). This article is protected by copyright. All rights reserved.","J Med Virol","Guo, Fei Ran","32369203"],"abstract":["The paper entitled \"The impact of COPD and smoking history on the severity of Covid-19: A systemic review and meta-analysis.\" published in Journal of Medical Virology on 15 April, 20201. The results revealed the pooled OR of COPD and the development of severe Covid-19 was 4.38 (Fixed effect model, 95% CI: 2.34-8.20), while the OR of ongoing smoking was 1.98 (Fixed effect model, 95% CI: 1.29-3.05). This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Guo, Fei Ran"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369203","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/jmv.25967","keywords":["covid-19","meta-analysis","smoking"],"topics":["Mechanism","Diagnosis"],"weight":1,"_version_":1666138496270598145,"score":83.77417},{"pmid":32408793,"title":"Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression.","text":["Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression.","OBJECTIVE: To investigate the association between hypertension and outcome in patients with Coronavirus Disease 2019 (COVID-19) pneumonia. METHODS: We performed a systematic literature search from several databases on studies that assess hypertension and outcome in COVID-19. Composite of poor outcome, comprising of mortality, severe COVID-19, acute respiratory distress syndrome (ARDS), need for intensive care unit (ICU) care and disease progression were the outcomes of interest. RESULTS: A total of 6560 patients were pooled from 30 studies. Hypertension was associated with increased composite poor outcome (risk ratio (RR) 2.11 (95% confidence interval (CI) 1.85, 2.40), p < 0.001; I(2), 44%) and its sub-group, including mortality (RR 2.21 (1.74, 2.81), p < 0.001; I(2), 66%), severe COVID-19 (RR 2.04 (1.69, 2.47), p < 0.001; I(2) 31%), ARDS (RR 1.64 (1.11, 2.43), p = 0.01; I(2),0%, p = 0.35), ICU care (RR 2.11 (1.34, 3.33), p = 0.001; I(2) 18%, p = 0.30), and disease progression (RR 3.01 (1.51, 5.99), p = 0.002; I(2) 0%, p = 0.55). Meta-regression analysis showed that gender (p = 0.013) was a covariate that affects the association. The association was stronger in studies with a percentage of males < 55% compared to 55% (RR 2.32 v. RR 1.79). CONCLUSION: Hypertension was associated with increased composite poor outcome, including mortality, severe COVID-19, ARDS, need for ICU care and disease progression in patients with COVID-19.","J Renin Angiotensin Aldosterone Syst","Pranata, Raymond","Lim, Michael Anthonius","Huang, Ian","Raharjo, Sunu Budhi","Lukito, Antonia Anna","32408793"],"abstract":["OBJECTIVE: To investigate the association between hypertension and outcome in patients with Coronavirus Disease 2019 (COVID-19) pneumonia. METHODS: We performed a systematic literature search from several databases on studies that assess hypertension and outcome in COVID-19. Composite of poor outcome, comprising of mortality, severe COVID-19, acute respiratory distress syndrome (ARDS), need for intensive care unit (ICU) care and disease progression were the outcomes of interest. RESULTS: A total of 6560 patients were pooled from 30 studies. Hypertension was associated with increased composite poor outcome (risk ratio (RR) 2.11 (95% confidence interval (CI) 1.85, 2.40), p < 0.001; I(2), 44%) and its sub-group, including mortality (RR 2.21 (1.74, 2.81), p < 0.001; I(2), 66%), severe COVID-19 (RR 2.04 (1.69, 2.47), p < 0.001; I(2) 31%), ARDS (RR 1.64 (1.11, 2.43), p = 0.01; I(2),0%, p = 0.35), ICU care (RR 2.11 (1.34, 3.33), p = 0.001; I(2) 18%, p = 0.30), and disease progression (RR 3.01 (1.51, 5.99), p = 0.002; I(2) 0%, p = 0.55). Meta-regression analysis showed that gender (p = 0.013) was a covariate that affects the association. The association was stronger in studies with a percentage of males < 55% compared to 55% (RR 2.32 v. RR 1.79). CONCLUSION: Hypertension was associated with increased composite poor outcome, including mortality, severe COVID-19, ARDS, need for ICU care and disease progression in patients with COVID-19."],"journal":"J Renin Angiotensin Aldosterone Syst","authors":["Pranata, Raymond","Lim, Michael Anthonius","Huang, Ian","Raharjo, Sunu Budhi","Lukito, Antonia Anna"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32408793","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1177/1470320320926899","keywords":["covid-19","hypertension","coronavirus","mortality","severity"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666897319139737600,"score":83.0478}]}